PEAK6 Investments’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

PEAK6 Investments’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,000	Closed	-$5K	–	6736
2022 Q1	$5K	Hold	25,000	–	–	﹤0.01%	4910
2021 Q4	$14K	Hold	25,000	–	–	﹤0.01%	4860
2021 Q3	$15K	Hold	25,000	–	–	﹤0.01%	4827
2021 Q2	$19K	Buy	+25,000	New	+$15.2K	﹤0.01%	4737

Other funds holding IBER.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

PEAK6 Investments's IBER.WS Position: Q2 2022 in Review

PEAK6 Investments sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q2 2022, closing a stake of 25,000 shares — an estimated $5K sold.

PEAK6 Investments first reported a position in IBER.WS in Q2 2021 and held it in 4 quarters. The position peaked at $19K in Q2 2021. 37 funds tracked by Wall St. Rank hold IBER.WS as of Q2 2022.

PEAK6 Investments reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q2 2022 after selling out during the quarter.
PEAK6 Investments sold 25,000 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q2 2022, an estimated $5K.
PEAK6 Investments first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 4 quarters.
PEAK6 Investments's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $19K in Q2 2021.
37 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q2 2022.

Based on PEAK6 Investments's 13F filing for Q2 2022, filed 12 Aug 2022.